Data from 53 patients hospitalized for severe COVID-19 pneumonia and treated with remdesivir through a compassionate use program demonstrated clinical improvement in 68% of patients 18 days after treatment initiation, with 47% discharged and 7% died. At 28 days there was clinical improvement or discharge from the hospital in 84% of patients. Adverse reactions were reported in 60% of patients with the most common being increased hepatic enzymes, diarrhea, rash, renal impairment, and hypotension.
The FDA has provided guidance to health care providers and investigators on the administration and study of convalescent plasma collected from individuals who have recovered from COVID-19.
General Treatment Guidelines
The Infectious Diseases Society of America (IDSA) has published treatment guidelines for COVID-19. The guideline reviews data for hydroxychloroquine/chloroquine with and without azithromycin, lopinavir/ritonavir, corticosteroids, tocilizumab, and convalescent plasma. The writing panel rated available data to provide a low level of certainty on use as treatments, and recommended that use should be done in the context of a clinical trial. When clinical trials are not feasible, IDSA recommends that registries be established to help in the evaluation of the efficacy and safety of the drugs.
Prescribe Right COVID-19 Drug Tracker
We have added 3 drugs to the tracker:
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker